Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.
Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Aptar COO Steve Hagge on how the firm's close client relationships and FDA-approved dispensers give the firm an advantage in consumer packaging.
Morningstar markets editor Jeremy Glaser highlights some must-dos in 2013 for banks, Blackberry devices, frazzled investors, and corporate America's balance sheets.
©2012 Morningstar Advisor. All right reserved.